Longitudinal plasma protein profiling of newly diagnosed type 2 diabetes
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Longitudinal plasma protein profiling of newly diagnosed type 2 diabetes. / Gummesson, Anders; Björnson, Elias; Fagerberg, Linn; Zhong, Wen; Tebani, Abdellah; Edfors, Fredrik; Schmidt, Caroline; Lundqvist, Annika; Adiels, Martin; Bäckhed, Fredrik; Schwenk, Jochen M.; Jansson, Per Anders; Uhlén, Mathias; Bergström, Göran.
In: EBioMedicine, Vol. 63, 103147, 2021.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Longitudinal plasma protein profiling of newly diagnosed type 2 diabetes
AU - Gummesson, Anders
AU - Björnson, Elias
AU - Fagerberg, Linn
AU - Zhong, Wen
AU - Tebani, Abdellah
AU - Edfors, Fredrik
AU - Schmidt, Caroline
AU - Lundqvist, Annika
AU - Adiels, Martin
AU - Bäckhed, Fredrik
AU - Schwenk, Jochen M.
AU - Jansson, Per Anders
AU - Uhlén, Mathias
AU - Bergström, Göran
N1 - Funding Information: This work was supported by the Swedish Heart-Lung Foundation (# 20180324 ), the Swedish Research Council ( 2019-01140 ), the Erling Persson Foundation , the Knut and Alice Wallenberg Foundation, and the Swedish state under the agreement between the Swedish government and the county councils ( ALFGBG-929989 , ALFGBG-718851 ). Publisher Copyright: © 2020 The Authors
PY - 2021
Y1 - 2021
N2 - Background: Comprehensive proteomics profiling may offer new insights into the dysregulated metabolic milieu of type 2 diabetes, and in the future, serve as a useful tool for personalized medicine. This calls for a better understanding of circulating protein patterns at the early stage of type 2 diabetes as well as the dynamics of protein patterns during changes in metabolic status. Methods: To elucidate the systemic alterations in early-stage diabetes and to investigate the effects on the proteome during metabolic improvement, we measured 974 circulating proteins in 52 newly diagnosed, treatment-naïve type 2 diabetes subjects at baseline and after 1 and 3 months of guideline-based diabetes treatment, while comparing their protein profiles to that of 94 subjects without diabetes. Findings: Early stage type 2 diabetes was associated with distinct protein patterns, reflecting key metabolic syndrome features including insulin resistance, adiposity, hyperglycemia and liver steatosis. The protein profiles at baseline were attenuated during guideline-based diabetes treatment and several plasma proteins associated with metformin medication independently of metabolic variables, such as circulating EPCAM. Interpretation: The results advance our knowledge about the biochemical manifestations of type 2 diabetes and suggest that comprehensive protein profiling may serve as a useful tool for metabolic phenotyping and for elucidating the biological effects of diabetes treatments. Funding: This work was supported by the Swedish Heart and Lung Foundation, the Swedish Research Council, the Erling Persson Foundation, the Knut and Alice Wallenberg Foundation, and the Swedish state under the agreement between the Swedish government and the county councils (ALF-agreement).
AB - Background: Comprehensive proteomics profiling may offer new insights into the dysregulated metabolic milieu of type 2 diabetes, and in the future, serve as a useful tool for personalized medicine. This calls for a better understanding of circulating protein patterns at the early stage of type 2 diabetes as well as the dynamics of protein patterns during changes in metabolic status. Methods: To elucidate the systemic alterations in early-stage diabetes and to investigate the effects on the proteome during metabolic improvement, we measured 974 circulating proteins in 52 newly diagnosed, treatment-naïve type 2 diabetes subjects at baseline and after 1 and 3 months of guideline-based diabetes treatment, while comparing their protein profiles to that of 94 subjects without diabetes. Findings: Early stage type 2 diabetes was associated with distinct protein patterns, reflecting key metabolic syndrome features including insulin resistance, adiposity, hyperglycemia and liver steatosis. The protein profiles at baseline were attenuated during guideline-based diabetes treatment and several plasma proteins associated with metformin medication independently of metabolic variables, such as circulating EPCAM. Interpretation: The results advance our knowledge about the biochemical manifestations of type 2 diabetes and suggest that comprehensive protein profiling may serve as a useful tool for metabolic phenotyping and for elucidating the biological effects of diabetes treatments. Funding: This work was supported by the Swedish Heart and Lung Foundation, the Swedish Research Council, the Erling Persson Foundation, the Knut and Alice Wallenberg Foundation, and the Swedish state under the agreement between the Swedish government and the county councils (ALF-agreement).
KW - Longitudinal profiling
KW - Plasma proteomics
KW - Precision medicine
KW - Type 2 diabetes
U2 - 10.1016/j.ebiom.2020.103147
DO - 10.1016/j.ebiom.2020.103147
M3 - Journal article
C2 - 33279861
AN - SCOPUS:85097140729
VL - 63
JO - EBioMedicine
JF - EBioMedicine
SN - 2352-3964
M1 - 103147
ER -
ID: 276702850